Skip to main content
. Author manuscript; available in PMC: 2013 May 23.
Published in final edited form as: Mol Cancer Ther. 2009 Aug 11;8(8):2356–2365. doi: 10.1158/1535-7163.MCT-08-1183

Table 1.

List of compounds and their structures used in this study

Compound Structure
Eu-NDP-α-MSH 1 Eu-(DTPA)-Ser-Tyr-Ser-Nle-Glu-His-DPhe-Arg-Trp-Gly-Lys-Pro-
Val-NH2
Eu-DPLCE H-Tyr-c[DPen-Gly-Phe-Cys]-Phe-Lys(Eu-(DTPA))-NH2
Eu-CCK8 Eu-(DTPA)-Asp-Tyr-Nle-Gly-Trp-Nle-Asp-Phe-NH2
Delt II-[PG]15-MSH7 2 H-Deltorphin II-[Pro-Gly]15-MSH7-NH2
MSH7-Pego-[PG]6-Pego-
CCK6
3 Ac-MSH7-PEGO-[Pro-Gly]6-PEGO-CCK6-NH2
MSH7-Pego-[PG]3-K(Cy5)-
Pego-CCK6
Ac-MSH7-PEGO-[Pro-Gly]3-Lys(Cy5)-PEGO-CCK6-NH2
1

Eu-(DTPA)

1

2

Deltorphin II          MSH7

Tyr-DAla-Phe-Glu-Val-Val-Gly   Ser-Nle-Glu-His-DPhe-Arg-Trp

3

PEGO

3

CCK6

Nle-Gly-Trp-Nle-Asp-Phe